NuCana (NCNA) Rating Lowered to Hold at Zacks Investment Research

Zacks Investment Research lowered shares of NuCana (NASDAQ:NCNA) from a buy rating to a hold rating in a research note published on Saturday, Zacks.com reports.

According to Zacks, “NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company’s pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom. “

Shares of NASDAQ NCNA opened at $14.00 on Friday. The stock has a market capitalization of $514.01 million, a PE ratio of -24.56 and a beta of 4.31. NuCana has a fifty-two week low of $10.37 and a fifty-two week high of $32.00.

NuCana (NASDAQ:NCNA) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.06. On average, sell-side analysts expect that NuCana will post -1.07 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Capital International Investors acquired a new stake in NuCana in the 3rd quarter valued at about $35,885,000. Alps Advisors Inc. lifted its stake in NuCana by 30.6% in the 4th quarter. Alps Advisors Inc. now owns 73,678 shares of the company’s stock valued at $1,068,000 after purchasing an additional 17,259 shares during the last quarter. Finally, Partner Fund Management L.P. lifted its stake in NuCana by 14.9% in the 4th quarter. Partner Fund Management L.P. now owns 447,420 shares of the company’s stock valued at $6,488,000 after purchasing an additional 58,062 shares during the last quarter. Institutional investors own 34.02% of the company’s stock.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer.

Read More: How Do Mutual Funds Work?

Get a free copy of the Zacks research report on NuCana (NCNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.